FDA Approves New Immunotherapy Drug for Bladder Cancer

The FDA has approved atezolizumab (Tecentriq®) for the treatment of some patients with urothelial carcinoma, the most common type of...

Blood Test for Genetic Changes in Tumors Shows Promise as Alternative to Tumor Biopsy

The largest study of its kind to date has shown that a test that assesses DNA mutations and other changes...

New on NCI’s Websites for June 2016

An NCI Cancer Currents blog post that provides updates on new NCI websites and other online content of interest to...

Early-Stage Cancer Trials Support Promise of Precision Medicine, Immunotherapy

Encouraging findings from several early-stage clinical trials featured at the 2016 American Society of Clinical Oncology annual meeting support the...

Extended Adjuvant Therapy Beneficial for Some Women with Breast Cancer

Results from a recent clinical trial showed that extending adjuvant therapy with an aromatase inhibitor to 10 years after initial...

The Moonshot Blue Ribbon Panel: Moving Toward a Final Report

An update on the activities of the National Cancer Moonshot Initiative’s Blue Ribbon Panel and its work to develop a...

Prognosis Discussions Improve Understanding of Illness for Patients with Terminal Cancer

Many patients with advanced, incurable cancer have a poor understanding of their prognosis or life expectancy, a new study shows....

The Cancer Moonshot Summit: Reaching New Heights

A recap of the Cancer Moonshot national summit hosted by Vice President Joe Biden in Washington, D.C., on June 29,...

Setting the Stage for the Next Decade of Tobacco Control Research

A new report from an NCI working group lays out recommended priorities to help shape the institute’s future tobacco control...